{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:28:28Z","timestamp":1789244908876,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000808"],"award-info":[{"award-number":["82000808"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BAB206094"],"award-info":[{"award-number":["20212BAB206094"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["jxsq2020101090"],"award-info":[{"award-number":["jxsq2020101090"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejphar.2023.175811","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:04:50Z","timestamp":1685099090000},"page":"175811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis"],"prefix":"10.1016","volume":"952","author":[{"given":"Xianlong","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimou","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175811_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.175811_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.175811_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving role for pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejphar.2023.175811_bib4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2023.175811_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2023.175811_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.175811_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.14218\/JCTH.2017.00056","article-title":"Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): review of phase 2 and 3 trials","volume":"6","author":"Connolly","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.ejphar.2023.175811_bib8","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/db20-0209","article-title":"The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman primates","volume":"69","author":"Cui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.175811_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2023.175811_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cell. Mol Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.175811_bib11","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse models of nonalcoholic steatohepatitis: towards optimization of their relevance to human nonalcoholic steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.175811_bib12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2023.175811_bib13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jada.2007.07.017","article-title":"Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up","volume":"107","author":"Franz","year":"2007","journal-title":"J. Am. Diet Assoc."},{"key":"10.1016\/j.ejphar.2023.175811_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120763","article-title":"Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo","volume":"271","author":"Geng","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejphar.2023.175811_bib15","doi-asserted-by":"crossref","first-page":"eaaz9890","DOI":"10.1126\/sciadv.aaz9890","article-title":"Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia","volume":"6","author":"Gilroy","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2023.175811_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.28523","article-title":"Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice","volume":"64","author":"Gong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.175811_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.175811_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2023.175811_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175811_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fnins.2015.00092","article-title":"GLP-1 based therapeutics: simultaneously combating T2DM and obesity","volume":"9","author":"Heppner","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2023.175811_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bbadis.2018.06.023","article-title":"Animal models of NAFLD from a hepatologist's point of view","volume":"1865","author":"Jahn","year":"2019","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2023.175811_bib22","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2023.175811_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3803\/EnM.2020.781","article-title":"Effects of glucagon-like peptide-1 analogue and fibroblast growth factor 21 combination on the atherosclerosis-related process in a type 2 diabetes mouse model","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol. Metab. (Seoul)."},{"key":"10.1016\/j.ejphar.2023.175811_bib24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.175811_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/path.4829","article-title":"Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances","volume":"241","author":"Lau","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejphar.2023.175811_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120447","article-title":"Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy","volume":"264","author":"Liang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejphar.2023.175811_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ebiom.2019.02.037","article-title":"Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output","volume":"41","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2023.175811_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118457","article-title":"Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db\/db mice","volume":"261","author":"Liu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2023.175811_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.175811_bib30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","article-title":"iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy","volume":"24","author":"Lynch","year":"2016","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2023.175811_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2023.175811_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2023.175811_bib33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2023.175811_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2023.175811_bib35","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2023.175811_bib36","doi-asserted-by":"crossref","first-page":"11077","DOI":"10.3748\/wjg.v21.i39.11077","article-title":"Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance","volume":"21","author":"St\u00e5l","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2023.175811_bib37","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.175811_bib38","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbadis.2015.02.012","article-title":"Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet","volume":"1852","author":"Tanaka","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2023.175811_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2023.175811_bib40","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1210\/en.2012-1211","article-title":"Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys","volume":"153","author":"V\u00e9niant","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2023.175811_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2023.175811_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1039\/C8BM01096J","article-title":"One-month zero-order sustained release and tumor eradication after a single subcutaneous injection of interferon alpha fused with a body-temperature-responsive polypeptide","volume":"7","author":"Wang","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejphar.2023.175811_bib43","article-title":"Thermoresponsive and protease-cleavable interferon-polypeptide conjugates with spatiotemporally programmed two-step release kinetics for tumor therapy","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejphar.2023.175811_bib44","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/bc300603k","article-title":"Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation","volume":"24","author":"Xu","year":"2013","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejphar.2023.175811_bib45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2023.175811_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13287-021-02205-z","article-title":"Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice","volume":"12","author":"Xue","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ejphar.2023.175811_bib47","article-title":"Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175811_bib48","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2174\/1389201015666140515124838","article-title":"Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation","volume":"14","author":"Ye","year":"2013","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.ejphar.2023.175811_bib49","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","article-title":"Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease","volume":"40","author":"Yilmaz","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.175811_bib50","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2023.175811_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends Pharmacol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923003229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923003229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:17:33Z","timestamp":1757978253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923003229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":51,"alternative-id":["S0014299923003229"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175811","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175811"}}